These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8131761)

  • 1. Hypersensitivity reactions to streptokinase in patients with high pre-treatment antistreptokinase antibody and neutralisation titres.
    Lee HS; Yule S; McKenzie A; Cross S; Reid T; Davidson R; Jennings K
    Eur Heart J; 1993 Dec; 14(12):1640-3. PubMed ID: 8131761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase.
    Lee HS; Cross S; Davidson R; Reid T; Jennings K
    Eur Heart J; 1993 Jan; 14(1):84-9. PubMed ID: 8432298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antistreptokinase titres after intravenous streptokinase.
    Jalihal S; Morris GK
    Lancet; 1990 Jan; 335(8683):184-5. PubMed ID: 1967665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How safe is the readministration of streptokinase?
    Lee HS
    Drug Saf; 1995 Aug; 13(2):76-80. PubMed ID: 7576266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG.
    Fears R; Ferres H; Glasgow E; Standring R; Hogg KJ; Gemmill JD; Burns JM; Rae AP; Dunn FG; Hillis WS
    Br Heart J; 1992 Aug; 68(2):167-70. PubMed ID: 1389731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction.
    Fears R; Hearn J; Standring R; Anderson JL; Marder VJ
    Am Heart J; 1992 Aug; 124(2):305-14. PubMed ID: 1636574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction.
    Patel S; Jalihal S; Dutka DP; Morris GK
    Br Heart J; 1993 Aug; 70(2):119-21. PubMed ID: 8038019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptokinase resistance: when might streptokinase administration be ineffective?
    Buchalter MB; Suntharalingam G; Jennings I; Hart C; Luddington RJ; Chakraverty R; Jacobson SK; Weissberg PL; Baglin TP
    Br Heart J; 1992 Nov; 68(5):449-53. PubMed ID: 1467027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intrapleural streptokinase administration on antistreptokinase antibody level in patients with loculated pleural effusions.
    Laisaar T; Pullerits T
    Chest; 2003 Feb; 123(2):432-5. PubMed ID: 12576362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersensitivity reactions to streptokinase.
    Singh J; Hart G
    Eur Heart J; 1994 Aug; 15(8):1153-4. PubMed ID: 7988614
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug eruptions and isotypic antibody responses to streptokinase after infusions of anisoylated plasminogen-streptokinase complex (APSAC, anistreplase).
    Dykewicz MS; McMorrow NK; Davison R; Fintel DJ; Zull CC; Rutledge JL
    J Allergy Clin Immunol; 1995 May; 95(5 Pt 1):1020-8. PubMed ID: 7751498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antistreptokinase titres after intravenous streptokinase.
    Lancet; 1990 Mar; 335(8688):534. PubMed ID: 1968541
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anaphylactic reaction in streptokinase therapy].
    Hohage H; Schulte B; Pfeiff B; Pullmann H
    Wien Klin Wochenschr; 1993; 105(6):176-8. PubMed ID: 8475630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat thrombolysis.
    Cross D
    Aust N Z J Med; 1993 Dec; 23(6):749-52. PubMed ID: 8141718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet reactivity and streptokinase resistance following antecedent streptokinase therapy for myocardial infarction.
    Gorog DA; Ahmed N; Davies GJ
    Cardiology; 1999; 91(1):56-9. PubMed ID: 10393399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypersensitive reactions on readministration of streptokinase following acute myocardial infarction.
    Sahay RN; Kalantri SP; Gupta OP
    J Assoc Physicians India; 1994 Oct; 42(10):815. PubMed ID: 7876052
    [No Abstract]   [Full Text] [Related]  

  • 17. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
    Crabbe SJ; Grimm AM; Hopkins LE
    Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should streptokinase be readministered? Insights from recent studies of antistreptokinase antibodies.
    Cross DB
    Med J Aust; 1994 Jul; 161(2):100-1. PubMed ID: 8028530
    [No Abstract]   [Full Text] [Related]  

  • 19. The incidence and mechanism of hypotension following thrombolytic therapy for acute myocardial infarction with streptokinase-containing agents--lack of relationship to pretreatment streptokinase resistance.
    Gemmill JD; Hogg KJ; Douglas JT; Dunn FG; Lowe GD; Rae AP; Hillis WS
    Eur Heart J; 1993 Jun; 14(6):819-25. PubMed ID: 8325311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy.
    Elliott JM; Cross DB; Cederholm-Williams SA; White HD
    Am J Cardiol; 1993 Mar; 71(8):640-5. PubMed ID: 8447258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.